GT BIOPHARMA, INC. Payments of Loan Costs
GT BIOPHARMA, INC. (GTBP) reported Payments of Loan Costs of $0 for the 6-month period ending 2020-06-30, per its 10-Q/A filed 2020-08-18.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfLoanCosts · last filed 2020-08-18
- GT BIOPHARMA, INC. payments of loan costs for the quarter ending 2020-06-30 was $0.00.
- GT BIOPHARMA, INC. payments of loan costs for the quarter ending 2020-03-31 was $0.00.
- GT BIOPHARMA, INC. payments of loan costs for the quarter ending 2019-12-31 was $0.00.
- GT BIOPHARMA, INC. payments of loan costs for the quarter ending 2019-09-30 was $0.00.
- GT BIOPHARMA, INC. payments of loan costs for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- GT BIOPHARMA, INC. payments of loan costs for fiscal 2018 was $533.00K.
- GT BIOPHARMA, INC. payments of loan costs for fiscal 2017 was $0.00.
| Period end | Payments of Loan Costs 3 month | Payments of Loan Costs 6 month | Payments of Loan Costs 9 month | Payments of Loan Costs 12 month |
|---|---|---|---|---|
| 2020-06-30 | $0.00 derived: 10-Q/A 6 month − 10-Q 3 month · filed 2020-08-18 | $0.00 10-Q/A · filed 2020-08-18 | $0.00 derived: sum of 3 quarters · filed 2020-08-18 | $0.00 derived: sum of 4 quarters · filed 2020-08-18 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-15 | $0.00 derived: sum of 2 quarters · filed 2020-05-15 | $0.00 derived: sum of 3 quarters · filed 2020-05-15 | $0.00 derived: sum of 4 quarters · filed 2020-08-18 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | $0.00 derived: sum of 2 quarters · filed 2020-03-27 | $0.00 derived: sum of 3 quarters · filed 2020-08-18 | $0.00 10-K · filed 2020-03-27 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q/A 6 month · filed 2019-11-14 | $0.00 derived: sum of 2 quarters · filed 2020-08-18 | $0.00 10-Q · filed 2019-11-14 | $0.00 derived: sum of 4 quarters · filed 2020-08-18 |
| 2019-06-30 | $0.00 derived: 10-Q/A 6 month − 10-Q 3 month · filed 2020-08-18 | $0.00 10-Q/A · filed 2020-08-18 | $0.00 derived: sum of 3 quarters · filed 2020-08-18 | $0.00 derived: sum of 4 quarters · filed 2020-08-18 |
| 2019-03-31 | $0.00 10-Q · filed 2020-05-15 | $0.00 derived: sum of 2 quarters · filed 2020-05-15 | $0.00 derived: sum of 3 quarters · filed 2020-05-15 | $0.00 derived: sum of 4 quarters · filed 2020-05-15 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | $0.00 derived: sum of 2 quarters · filed 2020-03-27 | $0.00 derived: sum of 3 quarters · filed 2020-03-27 | $533.00K 10-K · filed 2020-03-27 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $0.00 derived: sum of 2 quarters · filed 2019-11-14 | $533.00K 10-Q · filed 2019-11-14 | $533.00K derived: sum of 4 quarters · filed 2019-11-14 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $533.00K 10-Q · filed 2019-08-14 | $533.00K derived: sum of 3 quarters · filed 2019-08-14 | $533.00K derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-03-31 | $533.00K 10-Q · filed 2019-05-15 | $533.00K derived: sum of 2 quarters · filed 2019-05-15 | $533.00K derived: sum of 3 quarters · filed 2019-05-15 | $533.00K derived: sum of 4 quarters · filed 2019-05-15 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-29 | $0.00 derived: sum of 2 quarters · filed 2019-03-29 | $0.00 derived: sum of 3 quarters · filed 2019-03-29 | $0.00 10-K · filed 2019-03-29 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $0.00 derived: sum of 2 quarters · filed 2018-11-14 | $0.00 10-Q · filed 2018-11-14 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | $0.00 10-Q · filed 2018-08-14 | ||
| 2017-03-31 | $0.00 10-Q · filed 2018-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |